Skip to Main Content
For healthcare professionals

A Phase I, open label study of SIRPα antagonist (BI 770371) with or without ezabenlimab (PD-1 inhibitor) in patients with advanced solid tumors1,2

SIRPα antagonist: NCT05327946 (1501-0001)
SIRPα antagonist: NCT05327946 (1501-0001)

*Treatments to be given as IV infusion Q3W.
AE, adverse event; DLT, dose-limiting toxicity; ECOG PS, Eastern Cooperative Oncology Group performance status; IV, intravenous; MTD, maximum tolerated dose; PD-1, programmed cell death protein-1; Q3W, every 3 weeks; RECIST, Response Evaluation Criteria in Solid Tumours.

References

  1. ClinicalTrials.gov. NCT05327946. https://clinicaltrials.gov/ct2/show/NCT05327946 (Accessed: July 2025).

  2. Wang JS, et al. ASCO 2025. Oral Presentation.